These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3147279)

  • 1. The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment.
    Sainouchi R; Terata N; Kodama M
    Jpn J Cancer Res; 1988 Nov; 79(11):1247-53. PubMed ID: 3147279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
    Hostetler LW; Romerdahl CA; Kripke ML
    Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [TNF-alpha gene therapy for nonimmunogenic tumor using immunogenic variant induced with mutagen (N-methyl-N'-nitro-N-nitrosoguanidine)].
    Mekata E; Terata N; Kodama M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Feb; 19(1):69-79. PubMed ID: 8681029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
    Elliott BE; Carlow DA; Ivimey L; Arnold M; Hampton N; Bosman P
    Cancer Res; 1987 Sep; 47(18):4915-23. PubMed ID: 2441856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assay.
    Simcik W; Sheu TL; LeGrue SJ
    Cancer Immunol Immunother; 1989; 30(4):219-26. PubMed ID: 2598191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tumor-associated transplantation antigens of sublines of methylcholanthrene-induced murine tumors passaged separately in vivo for over a decade.
    Hines DL
    Cancer Res; 1986 Oct; 46(10):4921-6. PubMed ID: 3489516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.
    Van Pel A; Boon T
    Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4718-22. PubMed ID: 6981814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic variants of a murine fibrosarcoma induced by mutagenesis: requirement of viable cells for antigen-specific cross-protection.
    LeGrue SJ; Simcik WJ; Frost P
    Cancer Res; 1987 Aug; 47(16):4413-6. PubMed ID: 3607772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic variants isolated from a mutagen-treated guinea pig fibrosarcoma.
    Zbar B; Sukumar S; Tanio Y; Terata N; Hovis J
    Cancer Res; 1984 Nov; 44(11):5079-85. PubMed ID: 6488168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mutagens on the immunogenicity of murine tumor cells: immunological and biochemical evidence for altered cell surface antigens.
    Altevogt P; von Hoegen P; Leidig S; Schirrmacher V
    Cancer Res; 1985 Sep; 45(9):4270-7. PubMed ID: 4028013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction of immunogenic variant of a murine fibrosarcoma].
    Kobayashi M; Yamagishi H; Nomi S; Ueda Y; Hayashi T; Oka T
    Nihon Geka Gakkai Zasshi; 1992 Nov; 93(11):1372-7. PubMed ID: 1448043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
    Siesjö P; Visse E; Lindvall M; Salford L; Sjögren HO
    Cancer Immunol Immunother; 1993 Jul; 37(1):67-74. PubMed ID: 8513454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to somatic cell hybrids between ultraviolet radiation-induced regressor and spontaneous progressor C3H mouse tumor cells.
    Chen PW; Kaba DS; Ananthaswamy HN
    Cancer Res; 1990 Mar; 50(5):1544-9. PubMed ID: 2137370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour cell variants with increased immunogenicity obtained by mutagen treatment.
    Boon T; Maryanski J
    Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.